PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune ...
T-cell-specific surface glycoprotein CD28, also known as TP44, is a single-pass type I membrane protein that contains one Ig-like V-type (immunoglobulin-like) domain. It is a key co-stimulatory ...
Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer -RNDO-564 is designed to deliver safe and ...
Cancer is a notoriously complex monster; hydra-like in its ability to seemingly grow new heads with each one severed. Although significant progress has been made in the development of oncologic ...
LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership ...
SINGAPORE, July 12, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, ...
Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of ...
Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.
Treatment with the investigational bispecific antibody ubamatamab (REGN4018) alone or in combination with the PD-1 inhibitor cemiplimab (Libtayo) appeared to be safe and demonstrated activity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback